3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
3
Completed
3
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Melanoma
24
Carcinoma, Renal Cell
15
Carcinoma, Non-Small-Cell Lung
15
Neoplasm Metastasis
12
Urinary Bladder Neoplasms
6
Sarcoma
6
Prostatic Neoplasms
6
Lung Neoplasms
6
Pancreatic Neoplasms
5
Neoplasms
5
Kidney Neoplasms
5
Ovarian Neoplasms
4
Glioblastoma
4
Carcinoma, Transitional Cell
4
Uveal Melanoma
3
Small Cell Lung Carcinoma
3
Myelodysplastic Syndromes
3
Mesothelioma
3
Histiocytoma, Malignant Fibrous
3
Colorectal Neoplasms
3
Chordoma
3
Carcinoma, Neuroendocrine
3
Carcinoma, Merkel Cell
3
Breast Neoplasms
3
Brain Neoplasms
3
Urogenital Neoplasms
2
Urethral Neoplasms
2
Ureteral Neoplasms
2
Triple Negative Breast Neoplasms
2
Thyroid Neoplasms
2
Interventions
Cyclophosphamide
35
fludarabine
18
Methotrexate
17
fludarabine phosphate
16
Dexamethasone
16
blinatumomab
15
Vincristine
15
Cytarabine
14
Melphalan
12
Tacrolimus
11
Etoposide
11
pegaspargase
10
Whole-Body Irradiation
9
Mercaptopurine
9
Calcium Dobesilate
9
merphos
8
Dasatinib
8
Busulfan
8
Asparaginase
8
Thiotepa
7
Prednisone
7
Mycophenolic Acid
7
Leucovorin
7
Granulocyte Colony-Stimulating Factor
7
Doxorubicin
7
prednylidene
6
ponatinib
6
calaspargase pegol
6
Stem Cell Transplantation
6
Specimen Handling
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Ipilimumab
×
Clear all
NCT00586391
2026-02-06
CRETI-NH
Baylor College of Medicine
Phase 1
Active not recruiting
14 enrolled